Topics

Ixazomib Improves PFS as Frontline Maintenance in Multiple Myeloma

12:42 EST 7 Nov 2019 | OncLive

Ixazomib significantly improved progression-free survival as a first-line maintenance therapy compared with placebo in adult patients with multiple myeloma who have not undergone stem cell transplantation, meeting the primary endpoint of the phase III TOURMALINE-MM4 study.

Original Article: Ixazomib Improves PFS as Frontline Maintenance in Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "Ixazomib Improves PFS as Frontline Maintenance in Multiple Myeloma"

Quick Search

Relevant Topics

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...